Harris Teeter scores with wellness initiative
MATTHEWS, N.C. A nutritionally oriented wellness program from regional supermarket chain Harris Teeter is scoring points with consumers and health advocates, according to the company and a report in The Packer, a news resource for the fruit and vegetable industry.
Harris Teeter is mining a rich vein of consumer demand with its Your Wellness for Life program, launched in January. Following the rollout, which includes a 15-week meal plan for healthy eating as well as exercise and stress management programs, the North Carolina-based supermarket and pharmacy chain quickly caught on with customers in its six-state market area in the Southeast.
“The ‘Your Wellness for Life’ program is a life enhancement program, not simply a weight management program, though aspects of it can be used to help achieve and maintain a healthy body weight,” the company explains.
Harris Teeter partnered with Russ Greenfield, M.D., to create the program, including the meal plan and other guides to healthy living. Greenfield was honored as the inaugural recipient of The Golden Apple Award for excellence in teaching, and co-authored Healthy Child, Whole Child (HarperCollins 2001), which was named Best Parenting Guide 2001 by the editors at Amazon.com.
Publix postpones Miracle Mile GreenWise opening
VERO BEACH, Fla. Publix Super Markets has placed on hold plans to open a Publix GreenWise organic grocer here, according to reports published Wednesday.
Plans for the Vero Beach store have slowed while the grocer focuses on opening its GreenWise concept in Boca Raton, Kim Jaeger, Publix spokeswoman, told Stuart News Group.
According to the Stuart News report, Publix had announced last September the first GreenWise Market would open on Miracle Mile in Vero Beach during the third quarter of 2008.
FDA approves new cancer drug from Cephalon
WASHINGTON The Food and Drug Administration ahs announced its approval of Cephalon’s new cancer drug, Treanda. This recent approval hopes to raise the company’s shares, which have fallen 29 percent since June, published reports claim.
Treanda, indicated for chronic lymphocytic leukemia, was granted priority review by the FDA. The FDA approval of Treanda will mark the first big step in the oncology department for Cephalon, which normally makes its sales on pain relievers and treatments for central-nervous-system disorders. According to reports, the approval of this drug will bring it close to competing with major drug companies.
The approval of Treanda not only is expected to raise the share price of the company, but will also pave the way for Cephalon to introduce more cancer-related drugs into the market. As a result, shares of Cephalon were up $2.79, or 4.7 percent, to $62.14.